The hypothesize that SBRT will limit or reverse tumor growth and thereby convert the borderline resectable disease or locally advanced disease in to a resectable tumor. Furthermore, we want to assess whether SBRT leads to an improved quality of life compared to IMRT.
Able to sign the informed consent and understand the consenting process
Completed neoadjuvant chemotherapy regimen
Patient is 18 years of age and older
Eastern Cooperative Oncology Group (ECOG) Status of 0-1.
Pregnant or lactating female patients of reproductive potential who are not willing to employ highly effective birth control from screening to 6 months after the last dose of radiation therapy.
Resectable pancreatic cancer (See addendum, NCCN Guidelines 2021, PANC-2)
Unresectable pancreatic cancer (See addendum, NCCN Guidelines 2021, PANC-6)
Patients who are unable to tolerate general anesthetic with full skeletal muscle blockade.
Parallel
Cyberknife
Radiation5-10 Gy/fraction.Average of 45 minutes every other day for a total of 5 sessions (1.5-2 weeks).
Resectability
Occurrence of meeting resectability criteria using NCCN (PAN-C) guidelines
Patient Reported Outcome (General) - European Organization for Research and Treatment of Cancer (EORTC).
Change in mean score from baseline of Quality of Life using EORTC QLQ-C30 questionnaire. Raw score is transformed to standardize with a lowest value of 0 and a highest of 100.
Patient Reported Outcome (Specific)European Organization for Research and Treatment of Cancer (EORTC).
Change in mean score from baseline of Quality of Life using EORTC PAN26 questionnaire. Raw score is transformed to standardize with a lowest value of 0 and a highest of 100.
Click on the lead sponsor to view all of their trials.
